These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17351762)

  • 1. Influence of CCR5-Delta32 genotype in Spanish population with multiple sclerosis.
    Otaegui D; Ruíz-Martínez J; Olaskoaga J; Emparanza JI; López de Munain A
    Neurogenetics; 2007 Aug; 8(3):201-5. PubMed ID: 17351762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Meta-analysis of the relation between chemokine receptor 5 delta32 polymorphism and multiple sclerosis susceptibility.
    Song GG; Lee YH
    Immunol Invest; 2014; 43(4):299-311. PubMed ID: 24295368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis.
    Pulkkinen K; Luomala M; Kuusisto H; Lehtimäki T; Saarela M; Jalonen TO; Elovaara I
    Acta Neurol Scand; 2004 May; 109(5):342-7. PubMed ID: 15080861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course.
    Silversides JA; Heggarty SV; McDonnell GV; Hawkins SA; Graham CA
    Mult Scler; 2004 Apr; 10(2):149-52. PubMed ID: 15124759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCR5-Delta32 genetic polymorphism associated with benign clinical course and magnetic resonance imaging findings in Brazilian patients with multiple sclerosis.
    Kaimen-Maciel DR; Reiche EM; Brum Souza DG; Frota Comini ER; Bobroff F; Morimoto HK; Ehara Watanabe MA; Carvalho De Oliveira J; Matsuo T; Lopes J; Donadi EA
    Int J Mol Med; 2007 Sep; 20(3):337-44. PubMed ID: 17671738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis.
    Møller M; Søndergaard HB; Koch-Henriksen N; Sorensen PS; Sellebjerg F; Oturai AB
    Acta Neurol Scand; 2014 Jan; 129(1):27-31. PubMed ID: 23668375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemokine receptor V Δ32 deletion in multiple sclerosis patients in Csongrád County in Hungary and the North-Bácska region in Serbia.
    Török N; Molnár K; Füvesi J; Karácsony M; Zsiros V; Fejes-Szabó A; Fiatal S; Ádány R; Somogyvári F; Stojiljković O; Vécsei L; Bencsik K
    Hum Immunol; 2015 Jan; 76(1):59-64. PubMed ID: 25500253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between synapsin III gene promoter SNPs and multiple sclerosis in Basque patients.
    Otaegui D; Zuriarrain O; Castillo-Triviño T; Aransay A; Ruíz-Martinez J; Olaskoaga J; Marti-Masso J; Lopez de Munain A
    Mult Scler; 2009 Jan; 15(1):124-8. PubMed ID: 18755822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of CCR5 delta32 deletion with early death in multiple sclerosis.
    Gade-Andavolu R; Comings DE; MacMurray J; Rostamkhani M; Cheng LS; Tourtellotte WW; Cone LA
    Genet Med; 2004; 6(3):126-31. PubMed ID: 15354329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemokine receptor 5 (CCR5) deletion polymorphism in North Indian patients with coronary artery disease.
    Sharda S; Gilmour A; Harris V; Singh VP; Sinha N; Tewari S; Ramesh V; Agrawal S; Mastana S
    Int J Cardiol; 2008 Feb; 124(2):254-8. PubMed ID: 17383752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No association of CCR5delta32 gene mutation with multiple sclerosis in Croatian and Slovenian patients.
    Ristić S; Lovrecić L; Starcević-Cizmarević N; Brajenović-Milić B; Jazbec SS; Barac-Latas V; Vejnović D; Sepcić J; Kapović M; Peterlin B
    Mult Scler; 2006 Jun; 12(3):360-2. PubMed ID: 16764352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis.
    Kantarci OH; Morales Y; Ziemer PA; Hebrink DD; Mahad DJ; Atkinson EJ; Achenbach SJ; De Andrade M; Mack M; Ransohoff RM; Lassmann H; Bruck W; Weinshenker BG; Lucchinetti CF
    J Neuroimmunol; 2005 Dec; 169(1-2):137-43. PubMed ID: 16182378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-10 Promoter and the CCR5 Polymorphisms in Iranian Azari Population with Multiple Sclerosis.
    Asgharzadeh M; Sanajoo D; Mahdavi Poor B; Samadi Kafil H; Gholizadeh P; Rashedi J
    Iran J Immunol; 2021 Sep; 18(3):241-248. PubMed ID: 34596589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between the chemokine receptor 5 delta32 polymorphism and rheumatoid arthritis: a meta-analysis.
    Lee YH; Bae SC; Song GG
    Mod Rheumatol; 2013 Mar; 23(2):304-10. PubMed ID: 22638733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemokine receptor CCR5 in interferon-treated multiple sclerosis.
    Sellebjerg F; Kristiansen TB; Wittenhagen P; Garred P; Eugen-Olsen J; Frederiksen JL; Sørensen TL
    Acta Neurol Scand; 2007 Jun; 115(6):413-8. PubMed ID: 17511851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A mutated CCR5 gene may have favorable prognostic implications in MS.
    Kantor R; Bakhanashvili M; Achiron A
    Neurology; 2003 Jul; 61(2):238-40. PubMed ID: 12874407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune response genes receptors expression and polymorphisms in relation to multiple sclerosis susceptibility and response to INF-β therapy.
    Karam RA; Rezk NA; Amer MM; Fathy HA
    IUBMB Life; 2016 Sep; 68(9):727-34. PubMed ID: 27346865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCR5 Delta32 polymorphism: associated with gallbladder cancer susceptibility.
    Srivastava A; Pandey SN; Choudhuri G; Mittal B
    Scand J Immunol; 2008 May; 67(5):516-22. PubMed ID: 18405329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CC chemokine receptor 5 Δ32 polymorphism: association analysis and allele distribution among cutaneous leishmaniasis patients from Pakistan.
    Sophie M; Hameed A; Muneer A; Samdani AJ; Saleem S; Azhar A
    J Cutan Pathol; 2016 Jul; 43(7):564-70. PubMed ID: 26970327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of interleukin-4 receptor alpha chain variants in multiple sclerosis.
    Hackstein H; Bitsch A; Bohnert A; Hofmann H; Weber F; Ohly A; Linington C; Mäurer M; Poser S; Rieckmann P; Bein G
    J Neuroimmunol; 2001 Feb; 113(2):240-8. PubMed ID: 11164908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.